[11C]ER-176([11C]ER-176) - 药物靶点：TSPO_在研适应症：神经炎症，阿尔茨海默症，炎症_专利_临床

概要

基本信息

药物类型

小分子化药、诊断用放射药物

别名

11C-ER176

靶点

TSPO

作用方式

抑制剂

作用机制

TSPO抑制剂(TSPO蛋白抑制剂)

治疗领域

神经系统疾病其他疾病免疫系统疾病+ [1]

在研适应症

神经炎症阿尔茨海默症炎症+ [2]

非在研适应症

肌萎缩侧索硬化原发性进行性失语糖尿病性胃轻瘫+ [5]

原研机构

University of Pisa

在研机构

National Institute of Mental Health

Columbia University

National Institute on Aging

+ [1]

非在研机构-

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C20H20ClN3O

InChIKeyASFLYNMYGAYKON-XFBLKYPGSA-N

CAS号1623028-18-1

关联

14

项与 [11C]ER-176 相关的临床试验

NCT05805839

/ Enrolling by invitation临床2期IIT

Advanced MR and PET Imaging in Inflammatory Demyelinating Diseases of the Central Nervous System

This purpose of this study is research the usefulness of MRI with PET/CT imaging for measuring brain inflammation and its relation to Multiple Sclerosis (MS).

开始日期2023-07-10

申办/合作机构

Mayo Clinic

NCT05547880

/ RecruitingN/AIIT

CNS Correlates of Extended Sleep Restriction

Chronic sleep restriction is ubiquitous in both the general population and the military. The deleterious effects of sleep loss on human alertness and cognitive performance have been documented in numerous studies dating back to the nineteenth century. Over the past decade, evidence has emerged indicating that chronic sleep restriction may also precipitate deleterious, long lasting neuropathological changes in the brain. The purpose of this study is to determine neuropathological effects of sleep restriction and identify physiological mechanisms that correlate with sleep loss-induced performance impairment.

开始日期2023-05-23

申办/合作机构

Walter Reed Army Institute of Research

[+2]

NCT06384378

/ Recruiting临床2期IIT

Central and Peripheral Immune Cross-talk in Alzheimer's Disease and Their Modulation by a Novel Immunotherapy

Inflammation could provide a new focus for therapeutic intervention. In this study, we will measure blood and cerebrospinal fluid (CSF) inflammation biomarkers and compare them to measurements of brain glial activation obtained by positron emission tomography (PET). In addition, we will determine the effect of low-dose interleukin-2 (IL-2) immunotherapy, given over 22 weeks, on these inflammation biomarkers.

开始日期2023-03-17

申办/合作机构

The Methodist Hospital Research Institute

100 项与 [11C]ER-176 相关的临床结果

登录后查看更多信息

100 项与 [11C]ER-176 相关的转化医学

登录后查看更多信息

100 项与 [11C]ER-176 相关的专利（医药）

登录后查看更多信息

12

项与 [11C]ER-176 相关的文献（医药）

2024-06-15·Journal of Labelled Compounds and Radiopharmaceuticals

An Improved HPLC Separation Method for TSPO Radioligand [¹¹C]ER176 Clinical Production

Article

作者: Li, Kang‐Po ; Cai, Hancheng

ABSTRACTMitochondrial membrane translocator protein 18 kDa (TSPO) expression is increased in activated microglia, established as a plausible target of neuroinflammation imaging. [11C]ER176, specifically binding to TSPO, has been developed as the third generation of radioligand for PET imaging of TSPO, which showed the potential in better quantifying neuroinflammation than its predecessors. In the current study, we developed an automated radiosynthesis with an improved HPLC purification method for [11C]ER176 clinical production. The improved HPLC separation was integrated into the automated production of [11C]ER176 using a reverse phase semi‐preparative HPLC column with an isocratic pump and the mixture of methanol and 50 mM ammonium acetate as the mobile phase. The fraction corresponding to [11C]ER176 was collected around 8.5–9.0 min without the risk of getting contaminations from nearby impurities. The automated production process took about 30 min after end of bombardment (EOB) and the quality of the final product [11C]ER176 met all specifications for clinical use based on current US Pharmacopeia and FDA CGMP requirements.

2022-11-01·Drug Development Research

Acetamidobenzoxazolone scaffold as a promising translocator protein (18 kDa, TSPO) marker for neuroinflammation imaging: Advancement in last decennial period

Review

作者: Tiwari, Anjani Kumar ; Zhang, Ming‐Rong ; Adhikari, Anupriya

AbstractInflammation has been linked to the onset and progression of a wide range of neuropathological disorders. The well‐conserved outer mitochondrial membrane 18 kDa translocator protein (TSPO) is perceived as an in vivo neuroinflammation marker. A dearth of a reference region, genetic disparity influencing the ligand's affinity for TSPO, and a substantial signal in the endothelium of the brain veins contributes toward complications in quantifying TSPO positron emission tomography (PET) image. Up to the present time several radiotracers based on different pharmacophore such as (R)[11C]PK11195, [18F]DPA714, [11C]PBR28, [11C]ER176, and many more have been recognized for envisaging the prominent TSPO level observed in neurological conditions. Recently acetamidobenzoxazolone (ABO) scaffold, a bicyclic ring system composed of a phenyl ring fused to a carbamate and its substituted radiolabelled analogues especially at C‐5 position has evidenced encouraging outcomes as next generation of TSPO PET ligands. Diverse ABO framework‐based TSPO ligands have been designed embracing imperative aspects such as lipophilicity, metabolic profile, and capability to penetrate the blood–brain barrier apart from least effect of polymorphism (rs6971). Over the years numerous systematic literature reviews compiling different structural class of TSPO ligands characterized on the grounds of their binding affinity and metabolite profile have been reported but none is especially focused toward a fascinating benzoxazolone scaffold. This review exclusively bestows an overview of the recent advancements on ABO derivatives with neuroinflammation imaging potential and emphases on the structural features accountable for visualizing TSPO in‐vivo with collation of published reports during last 10 years.

2022-07-04·Molecular Pharmaceutics

[¹⁸F]BIBD-239: ¹⁸F-Labeled ER176, a Positron Emission Tomography Tracer Specific for the Translocator Protein

Article

作者: Yan, Jun ; Yu, Ziyue ; Chen, Hualong ; Liu, Yajing ; Wu, Zehui ; Jiang, Zeng ; Cheng, Xuebo ; Ji, Xunming ; Zhang, Lu ; Sun, Yuli ; Yang, Tingyu ; Zheng, Wei

[¹¹C]ER176 has adequate sensitivity to image the human brain translocator protein (TSPO) in all three genotypes by positron emission tomography (PET). However, its clinical application is limited by the short half-life of ¹¹C (20.38 min). To overcome the deficiency of [¹¹C]ER176 and keep the pharmacophore features of ER176 to the maximum extent, we designed four fluorine-labeled ER176 derivatives using the deuterium method. In vitro competition binding confirmed that the designed compounds had high affinity for TSPO. Biodistribution experiments showed that tissues with high expression of TSPO had high uptake of these compounds, as well as that the compound showed high brain penetration and mild defluorination in vivo. Therefore, [¹⁸F]BIBD-239 with simple synthesis conditions was selected for further biological evaluation. Theoretical simulations showed that BIBD-239 and ER176 have similar binding modes and sites to Ala147-TSPO and Thr147-TSPO, which indicated that the tracers may have consistent sensitivity to the three affinity genotypes. In vitro autoradiography and in vivo PET studies of the ischemic rat brain showed dramatically higher uptake of [¹⁸F]BIBD-239 on the lesion site compared to the contralateral side with good brain kinetics. Additionally, [¹⁸F]BIBD-239 provided clear tumor PET images in a GL261 glioma model. Importantly, PET imaging and liquid chromatography-high-resolution mass spectrometry (LC-HRMS) results showed that in vivo defluorination and other metabolites of [¹⁸F]BIBD-239 did not interfere with brain imaging. Conclusively, [¹⁸F]BIBD-239, similar to ER176 with low polymorphism sensitivity, has simple labeling conditions, high labeling yield, high affinity, and high specificity for TSPO, and it is planned for further evaluation in higher species.

100 项与 [11C]ER-176 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病性胃轻瘫	临床2期	美国	Mayo Clinic	2021-05-10
神经炎症	临床2期	美国	Mayo Clinic	2021-03-30
阿尔茨海默症	临床2期	美国	National Institute on Aging	2020-11-17
肌萎缩侧索硬化	临床2期	美国	National Institute of Mental Health	2019-07-03
原发性进行性失语	临床2期	美国	National Institute of Mental Health	2019-07-03
额颞痴呆	临床2期	美国	National Institute of Mental Health	2019-07-03
亨廷顿舞蹈病	临床2期	美国	National Institute of Mental Health	2019-07-03
炎症	临床1期	美国	National Institute of Mental Health	2019-06-14
肌炎	临床1期	美国	National Institute of Mental Health	2019-06-14
类风湿关节炎	临床1期	美国	National Institute of Mental Health	2019-06-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03958630 (CTgov)	临床1期	延髓麻痹，进行性 \| 阿尔茨海默症 \| 神经退行性疾病 \| 额颞痴呆 \| 运动神经元疾病 \| 神经炎症 \| 39型常染色体隐性遗传性痉挛性截瘫 \| 亨廷顿舞蹈病 \| 痴呆 \| 额颞叶退化 \| 肌萎缩侧索硬化 \| 原发性进行性失语	13	Positron Emission Tomography (PET) Scan+11C-ER176+11C-PIB (Healthy Volunteers)	廠鬱蓋製蓋窪醖鏇憲淵(構範簾壓衊壓蓋鏇製簾) = 鏇膚構獵膚襯齋壓襯觸夢膚繭艱網襯網簾鹹憲 (獵鹹鑰觸築構衊淵鹽夢, 鬱壓築襯範窪齋憲鹹遞 ~ 製觸夢餘範淵構網繭齋) 更多	-	2024-05-01
				Positron Emission Tomography (PET) Scan+11C-ER176+11C-PIB (Subjects With Frontotemporal Dementia (FTD))	廠鬱蓋製蓋窪醖鏇憲淵(構範簾壓衊壓蓋鏇製簾) = 衊願積襯選簾築製壓鏇夢膚繭艱網襯網簾鹹憲 (獵鹹鑰觸築構衊淵鹽夢, 鏇艱夢膚鹽襯艱選蓋簾 ~ 鹹構齋衊鬱憲構窪築廠) 更多
NCT03744312 (CTgov)	临床1/2期	阿尔茨海默症 \| 炎症	9	Florbetaben+11C-ER176 (Cognitive Impairment)	淵鏇醖構築鑰網糧選廠(構網繭鑰齋蓋廠壓夢選) = 蓋膚鹽積壓鬱壓艱憲膚簾窪願壓餘鏇淵蓋築窪 (廠範餘願鏇醖築築鑰獵, 鹹齋鬱衊醖鑰襯餘網積 ~ 餘簾壓積膚齋膚獵獵繭) 更多	-	2023-09-13
				Florbetaben+11C-ER176 (No Cognitive Impairment)	淵鏇醖構築鑰網糧選廠(構網繭鑰齋蓋廠壓夢選) = 範窪鹹網鹹窪夢鏇壓蓋簾窪願壓餘鏇淵蓋築窪 (廠範餘願鏇醖築築鑰獵, 積獵襯餘齋廠淵簾選壓 ~ 簾鹽簾膚壓願窪衊憲簾) 更多
NCT04762719 (CTgov)	临床2/3期	糖尿病性胃轻瘫	12	Core biopsy of gastric muscle+PET/CT Scan (Diabetic Gastroparesis Subjects)	艱觸顧膚窪構選鑰糧遞(顧積襯夢艱衊鏇憲蓋鹽) = 製憲衊積顧願襯餘鏇鏇淵顧齋蓋積衊夢餘膚鑰 (範蓋膚窪淵醖製艱醖廠, 範襯顧襯廠網積襯遞壓 ~ 齋餘窪鏇獵構膚鬱膚壓) 更多	-	2023-04-18
				PET/CT Scan (Diabetic Without Gastroparesis Subjects)	艱觸顧膚窪構選鑰糧遞(顧積襯夢艱衊鏇憲蓋鹽) = 積夢積壓簾膚範糧膚蓋淵顧齋蓋積衊夢餘膚鑰 (範蓋膚窪淵醖製艱醖廠, 蓋積艱餘鏇鑰構壓鏇觸 ~ 鑰築鏇齋蓋製範襯夢顧) 更多
SNMMI2022	N/A	-	-	11C-ER176 (High-affinity binders)	範顧鏇齋膚艱醖廠選廠(顧夢淵廠蓋網襯衊膚範) = ICC was excellent. Variability and ICC were good even in small VOIs and PVC did not affect the results. 鹹壓窪簾獵築衊簾蓋網 (鏇餘遞膚鹹製憲窪廠襯 ) 更多	-	2022-08-08
				11C-ER176 (Mixed-affinity binders)